Carrington Laboratories Entered Supply and Trademark Agreement with Veterinary Products Laboratories for Acemannan Immunostimulant™
Carrington Laboratories, Inc., (Nasdaq: CARN) have agreed with Veterinary Products Laboratories (a division of Farnam Companies, Inc.; 9325468) for a supply and trademark agreement for Acemannan Immunostimulant™.
Acemannan Immunostimulant™ is a biologic injectable treatment for fibrosarcoma, a form of soft tissue cancer, in dogs and cats.
Under the terms of agreement, Carrington will supply Acemannan Immunostimulant™ to VPL under an exclusive agreement for a period of up to three years, during which VPL will be responsible for the exclusive sales and distribution of the product.
Find more details from the press release.
[Photo Credit: Farnam Pet]
Comment Preview